Clinical Trial Update: A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 multicenter trial evaluating 177Lu-DOTA-TATE with kidney dosimetry in patients with disseminated neuroendocrine tumors, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• 177Lu-DOTA-TATE (Lutetium-177 DOTATATE)

Snippet

Sponsor: Lund University Hospital | Conditions: Neuroendocrine Tumors, Liver Metastases | Phase 2 | Status: COMPLETED